Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Redhill Biophrma ADR (RDHL)

Redhill Biophrma ADR (RDHL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 232,868
  • Shares Outstanding, K 46,667
  • Annual Sales, $ 64,360 K
  • Annual Income, $ -76,170 K
  • 60-Month Beta 1.47
  • Price/Sales 3.58
  • Price/Cash Flow N/A
  • Price/Book 14.88
Trade RDHL with:

Options Overview Details

View History
  • Implied Volatility 95.30%
  • Historical Volatility 167.60%
  • IV Percentile 5%
  • IV Rank 3.97%
  • IV High 231.92% on 05/11/21
  • IV Low 89.65% on 06/16/21
  • Put/Call Vol Ratio 0.08
  • Today's Volume 921
  • Volume Avg (30-Day) 2,572
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 12,393
  • Open Int (30-Day) 26,559

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.48
  • Number of Estimates 2
  • High Estimate -0.46
  • Low Estimate -0.50
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +4.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.48 +14.73%
on 09/20/21
11.18 -54.03%
on 08/31/21
-2.62 (-33.76%)
since 08/27/21
3-Month
4.48 +14.73%
on 09/20/21
11.18 -54.03%
on 08/31/21
-1.83 (-26.26%)
since 06/25/21
52-Week
4.48 +14.73%
on 09/20/21
11.52 -55.38%
on 02/22/21
-4.95 (-49.06%)
since 09/25/20

Most Recent Stories

More News
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo

and , /PRNewswire/ -- (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP...

REDIF : 0.6700 (unch)
RDHL : 5.14 (+3.01%)
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal....

RDHL : 5.14 (+3.01%)
VTVT : 1.7200 (-6.01%)
CRVS : 7.67 (+12.79%)
SPRO : 19.47 (+3.95%)
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients

and , /PRNewswire/ --  (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary top-line data from the 475-patient global Phase 2/3 study with opaganib...

RDHL : 5.14 (+3.01%)
RHB-107 P2/3 COVID-19 Study South Africa Approval

RDHL : 5.14 (+3.01%)
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval

and , /PRNewswire/ --  (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that has joined the U.S. in approving the Phase 2/3 study with novel, once-daily,...

REDIF : 0.6700 (unch)
RDHL : 5.14 (+3.01%)
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis

Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.

REGN : 619.07 (-3.10%)
IRWD : 13.49 (+0.30%)
RGEN : 307.37 (-4.92%)
RDHL : 5.14 (+3.01%)
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

and , /PRNewswire/ -- (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results of a new preclinical study demonstrating opaganib's (ABC294640)efficacy...

RDHL : 5.14 (+3.01%)
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

and , /PRNewswire/ -- (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation at PAINWeek 2021 of three new analyses of Movantik(naloxegol) Phase...

RDHL : 5.14 (+3.01%)
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences

and , /PRNewswire/ --  (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in September:

RDHL : 5.14 (+3.01%)
Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More

Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.

REGN : 619.07 (-3.10%)
SNY : 48.12 (+0.38%)
INCY : 69.26 (+0.38%)
RDHL : 5.14 (+3.01%)
ACIU : 7.14 (+3.33%)
MOR : 12.37 (+1.56%)
SAVA : 68.53 (+10.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

RedHill Biopharma Ltd. is a specialty biopharmaceutical company, focused on gastrointestinal and infectious diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment is based in Raleigh, NC, and covers all areas relating...

See More

Key Turning Points

3rd Resistance Point 5.44
2nd Resistance Point 5.29
1st Resistance Point 5.22
Last Price 5.14
1st Support Level 5.00
2nd Support Level 4.85
3rd Support Level 4.78

See More

52-Week High 11.52
Fibonacci 61.8% 8.83
Fibonacci 50% 8.00
Fibonacci 38.2% 7.17
Last Price 5.14
52-Week Low 4.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar